Found 344 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will …
This Phase 1b, open-label, multicenter study will be conducted to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in subjects with PAH currently ssing Tyvaso. A minimum of 45 patients from 15 sites in the US will be enrolled in the study.
This is a pilot study in patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to …
The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. …
This is an interventional cohort study (n=10) that will involve external drainage of thoracic duct lymph in Surgical ICU patients with septic shock. The lymph drainage will continue for up to a maximum of 7 days and will be continued in those patients discharged from ICU back to the ward …
This is a phase 3, 56-week, multicenter, randomized, placebo controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). Subjects will be randomized to 1 of 2 treatment sequences: Sequence A: 0.5 g/kg IgPro20 for 24 weeks followed by 0.5 g/kg IgPro20 for 28 weeks or …
This study will help researchers better understand the management of psoriatic arthritis (PsA). The goals of this study are a) to better understand how PsA responds to biologic therapy b) to build a registry of data and blood from patients with PsA for future studies and c) to figure out …
Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes, which may be useful in the diagnosis, prognosis, and treatment of giant cell arteritis (GCA; temporal arteritis). Study participants are eligible if …
